Zeposia

ประเทศ: สหภาพยุโรป

ภาษา: โรมาเนีย

แหล่งที่มา: EMA (European Medicines Agency)

ซื้อเลย

สารออกฤทธิ์:

ozanimod clorhidrat de

มีจำหน่ายจาก:

Bristol-Myers Squibb Pharma EEIG

รหัส ATC:

L04AA38

INN (ชื่อสากล):

ozanimod

กลุ่มบำบัด:

Imunosupresoare

พื้นที่บำบัด:

Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative

ข้อบ่งชี้ในการรักษา:

Multiple sclerosisZeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. Ulcerative colitisZeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

สรุปสินค้า:

Revision: 5

สถานะการอนุญาต:

Autorizat

วันที่อนุญาต:

2020-05-20

แผ่นพับข้อมูลผู้ป่วย

                                41
B. PROSPECTUL
42
PROSPECT: INFORMAȚII PENTRU PACIENT
ZEPOSIA 0,23 MG CAPSULE
ZEPOSIA 0,46 MG CAPSULE
ZEPOSIA 0,92 MG CAPSULE
ozanimod
Acest medicament face obiectul unei monitorizări suplimentare. Acest
lucru va permite
identificarea rapidă de noi informații referitoare la siguranță.
Puteți să fiți de ajutor raportând orice
reacții adverse pe care le puteți avea. Vezi ultima parte de la pct.
4 pentru modul de raportare a
reacțiilor adverse.
CITIȚI CU ATENȚIE ȘI ÎN ÎNTREGIME ACEST PROSPECT ÎNAINTE DE A
ÎNCEPE SĂ LUAȚI ACEST MEDICAMENT
DEOARECE CONȚINE INFORMAȚII IMPORTANTE PENTRU DUMNEAVOASTRĂ.
-
Păstrați acest prospect. S-ar putea să fie necesar să-l recitiți.
-
Dacă aveți orice întrebări suplimentare, adresați-vă medicului
dumneavoastră sau farmacistului.
-
Acest medicament a fost prescris numai pentru dumneavoastră. Nu
trebuie să-l dați altor
persoane. Le poate face rău, chiar dacă au aceleași semne de boală
ca dumneavoastră.
-
Dacă manifestați orice reacții adverse, adresați-vă medicului
dumneavoastră sau farmacistului.
Acestea includ orice posibile reacții adverse nemenționate în acest
prospect. Vezi pct. 4.
CE GĂSIȚI ÎN ACEST PROSPECT
1.
Ce este Zeposia și pentru ce se utilizează
2.
Ce trebuie să știți înainte să luați Zeposia
3.
Cum să luați Zeposia
4.
Reacții adverse posibile
5.
Cum se păstrează Zeposia
6.
Conținutul ambalajului și alte informații
1.
CE ESTE ZEPOSIA ȘI PENTRU CE SE UTILIZEAZĂ
Zeposia conține substanța activă ozanimod, care aparține unei
grupe de medicamente care pot reduce
numărul de globule albe din sânge (limfocite) liber circulante în
organism.
Zeposia este indicat în următoarele boli:
-
Scleroză multiplă
-
Colită ulcerativă
Scleroză multiplă
Zeposia este indicat pentru tratamentul pacienților adulți cu
scleroză multiplă recurent-remisivă
(SMRR) cu boală activă.
•
Scleroza multiplă (SM) este o afecțiune în cadrul căreia sistemul
imunitar (sistemul de apărare
al organismului, inclus
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

สรุปลักษณะสินค้า

                                1
ANEXA I
REZUMATUL CARACTERISTICILOR PRODUSULUI
2
Acest medicament face obiectul unei monitorizări suplimentare. Acest
lucru va permite
identificarea rapidă de noi informații referitoare la siguranță.
Profesioniștii din domeniul sănătății sunt
rugați să raporteze orice reacții adverse suspectate. Vezi pct. 4.8
pentru modul de raportare a reacțiilor
adverse.
1.
DENUMIREA COMERCIALĂ A MEDICAMENTULUI
Zeposia 0,23 mg capsule
Zeposia 0,46 mg capsule
Zeposia 0,92 mg capsule
2.
COMPOZIȚIA CALITATIVĂ ȘI CANTITATIVĂ
Zeposia 0,23 mg capsule
Fiecare capsulă conține clorhidrat de ozanimod, echivalent cu
ozanimod 0,23 mg.
Zeposia 0,46 mg capsule
Fiecare capsulă conține clorhidrat de ozanimod, echivalent cu
ozanimod 0,46 mg.
Zeposia 0,92 mg capsule
Fiecare capsulă conține clorhidrat de ozanimod, echivalent cu
ozanimod 0,92 mg.
Pentru lista tuturor excipienților, vezi pct. 6.1.
3.
FORMA FARMACEUTICĂ
Capsulă.
Zeposia 0,23 mg capsule
Capsulă de culoare gri-deschis opac, 14,3 mm, inscripționată în
cerneală neagră cu textul „OZA” pe
capac și „0.23 mg” pe corp.
Zeposia 0,46 mg capsule
Capsulă cu corp de culoare gri-deschis opac și capac de culoare
portocalie opac, 14,3 mm,
inscripționată în cerneală neagră cu textul „OZA” pe capac
și „0.46 mg” pe corp.
Zeposia 0,92 mg capsule
Capsulă de culoare portocaliu opac, 14,3 mm, inscripționată în
cerneală neagră cu textul „OZA” pe
capac și „0.92 mg” pe corp.
3
4.
DATE CLINICE
4.1
INDICAȚII TERAPEUTICE
Scleroză multiplă
Zeposia este indicat pentru tratamentul pacienților adulți cu
scleroză multiplă recurent-remisivă
(SMRR) cu boală activă, așa cum este definită pe baza
caracteristicilor clinice sau imagistice.
Colită ulcerativă
Zeposia este indicat pentru tratamentul pacienților adulți cu
colită ulcerativă (CU) activă moderată și
severă, care au obținut un răspuns inadecvat, au pierdut răspunsul
sau au manifestat intoleranță la
terapia convențională sau la un medicament biologic.
4.2
DOZE 
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

เอกสารเป็นภาษาอื่น

แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย บัลแกเรีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า บัลแกเรีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เดนมาร์ก 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เยอรมัน 12-04-2024
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย เอสโตเนีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เอสโตเนีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อังกฤษ 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฝรั่งเศส 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อิตาลี 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลัตเวีย 12-04-2024
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ลิทัวเนีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลิทัวเนีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฮังการี 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปแลนด์ 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปรตุเกส 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวัก 12-04-2024
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย สโลวีเนีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวีเนีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฟินแลนด์ 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สวีเดน 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า นอร์เวย์ 12-04-2024
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ไอซ์แลนด์ 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ไอซ์แลนด์ 12-04-2024
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย โครเอเชีย 12-04-2024
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โครเอเชีย 12-04-2024

ค้นหาการแจ้งเตือนที่เกี่ยวข้องกับผลิตภัณฑ์นี้

ดูประวัติเอกสาร